查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
女性科技與精準醫療在女性健康領域的融合
市場調查報告書
商品編碼
1812611

女性科技與精準醫療在女性健康領域的融合

The Convergence of FemTech and Personalised Medicine in Women's Health
出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2個工作天內

價格
簡介目錄

本報告探討了女性科技與精準醫療的交匯，並分析了數位健康創新如何重塑女性健康格局。報告探討了女性科技從以消費者為中心的應用到臨床整合解決方案的演變過程、女性健康研究中持續存在的數據缺口，以及產生可靠真實世界證據所面臨的課題。

深入了解將數位科技與傳統藥物治療結合的策略、全面臨床試驗設計的重要性，以及製藥公司與女性科技新創公司之間合作的關鍵作用。本報告也探討了推動創新所需的商業和監管考量，並強調了透過協作和數據驅動的方法改善女性健康狀況所帶來的更廣泛的經濟和社會影響。

關鍵問題解答

  • 1.女性科技如何發展並融入主流醫療保健？
  • 2.造成女性健康資料缺口的因素有哪些？如何解決？
  • 3.數位科技如何在女性健康領域補充傳統藥物治療？
  • 4.藥廠與女性科技新創公司合作面臨哪些課題與機會？
  • 5.藥廠和女性科技公司如何為女性健康提供更有力的真實世界證據？
  • 6.女性科技領域的投資與創新面臨哪些障礙？
  • 7.臨床試驗如何更有包容性地納入女性，包括孕婦和哺乳期婦女？
  • 8.藥廠與女性科技公司成功合作需要哪些模式與策略？
  • 9.如何設計數位工具來提高依從性並為女性提供個人化護理？
  • 10.女性科技未來將對女性健康狀況以及更廣泛的醫療生態系統產生哪些影響？

主要企業

  • Clue
  • Evinova
  • IBSA UK
  • Theramex
  • UCB
  • QVin
  • Genentech
  • K'ept Health
  • TherapeuticsMD
  • Agile
  • Eli Health
  • Noom
  • Wisp
  • Incora Health
  • Aura Fertility
  • LiGalli Health
  • Novartis
  • ImageBiopsy Lab
  • Organon
  • Boston Consulting Group

參加專家的一部分清單

  • Evinova，數位健康實行領導R&D
  • IBSA UK英國事業部長
  • Theramex CEO
  • UCB，生產適齡期女性計劃·全球的·記錄磁頭

調查手法

本報告是基於獨立而簡潔的分析，這些分析源自於專有的產業研究以及對產業思想領袖的深入訪談。報告深入分析了製藥企業高管需要了解的關鍵發展和市場趨勢，以應對未來的機會和課題。每份報告的重點都基於對二手文獻的回顧和已發現的知識缺口。基於這些初步研究，我們創建了基於證據、由專家主導的討論指南，以確保我們的研究能夠解答最重要的問題。此外，我們採用嚴格的篩選標準，以確保受訪者有足夠的經驗、知識和資格就該主題發表意見。

我們報告的特點

FirstWord Reports 是值得信賴的行業領導者，專注於製藥業，為生物製藥專業人士和決策者提供深入、可操作的洞察。我們深厚的行業知識使我們能夠提供相關且有價值的洞察，幫助我們的客戶掌握新興趨勢，並有效應對複雜的課題。憑藉廣泛的研究以及來自頂尖專家和關鍵意見領袖的獨立、公正的見解，我們的報告能夠提供您所需的準確性和可靠性。獨家訪問獨家訪談和數據，以及持續的市場監測，確保全面了解市場動態。我們的報告涵蓋 40 多個動態疾病領域、包括 KOL 洞察和定量醫生調查在內的醫生情報以及行業專家對醫療事務、數位健康、銷售和營銷、市場准入和其他領域問題的看法，使您能夠做出更明智的、數據驅動的決策，並在快速變化的行業中保持競爭力。

簡介目錄

This report examines the intersection of FemTech and personalised medicine, analysing how digital health innovations are reshaping the landscape of women's health. It explores the evolution of FemTech from consumer-focused applications to clinically integrated solutions, the persistent data gap in women's health research and the challenges of generating robust real-world evidence.

Gain insights into strategies for integrating digital technologies with traditional pharmaceutical treatments, the importance of inclusive clinical trial design and the critical role of partnerships between pharmaceutical companies and FemTech startups. This report also addresses the commercial and regulatory considerations necessary for advancing innovation and highlights the broader economic and societal impact of improving women's health outcomes through collaborative, data-driven approaches.

Key Questions Answered:

  • 1. How is FemTech evolving and being integrated into mainstream healthcare?
  • 2. What factors contribute to the women's health data gap, and how can it be addressed?
  • 3. How can digital technologies complement traditional pharmaceutical treatments in women's health?
  • 4. What are the challenges and opportunities for partnerships between pharmaceutical companies and FemTech startups?
  • 5. How can pharma and FemTech generate more robust real-world evidence for women's health?
  • 6. What are the barriers to investment and innovation in FemTech, and how can they be overcome?
  • 7. How can clinical trials become more inclusive of women, including pregnant and breastfeeding populations?
  • 8. What models and strategies ensure successful collaboration between pharma and FemTech?
  • 9. How can digital tools be designed to improve adherence and personalise care for women?
  • 10. What is the future impact of FemTech on women's health outcomes and the broader healthcare ecosystem?

Key Companies:

  • Clue
  • Evinova
  • IBSA UK
  • Theramex
  • UCB
  • QVin
  • Genentech
  • K'ept Health
  • TherapeuticsMD
  • Agile
  • Eli Health
  • Noom
  • Wisp
  • Incora Health
  • Aura Fertility
  • LiGalli Health
  • Novartis
  • ImageBiopsy Lab
  • Organon
  • Boston Consulting Group

Partial List of Participating Experts:

  • Digital Health Implementation Lead R&D, Evinova
  • General Manager UK operations, IBSA UK
  • CEO, Theramex
  • Global Head of UCB's Women of Childbearing Age Program, UCB

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.